Conclusions
The most progress has been made on SARS-CoV E, highlighting specific structural requirements for its functions in the CoV life cycle as well as mechanisms behind its pathogenesis. Data shows that E is involved in critical aspects of the viral life cycle and that CoVs lacking E make promising vaccine candidates. The high mortality rate of certain CoVs, along with their ease of transmission, underpins the need for more research into CoV molecular biology which can aid in the production of effective anti-coronaviral agents for both human CoVs and enzootic CoVs.
- Forums
- ASX - By Stock
- BIT
- CoVs lacking E make promising vaccine candidates.
CoVs lacking E make promising vaccine candidates.
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BIT (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $19.85M |
Open | High | Low | Value | Volume |
2.2¢ | 2.3¢ | 2.2¢ | $8.562K | 389.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 228 | 2.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.3¢ | 1991719 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 365000 | 0.021 |
10 | 916111 | 0.020 |
10 | 1806701 | 0.019 |
10 | 1719892 | 0.018 |
6 | 614520 | 0.017 |
Price($) | Vol. | No. |
---|---|---|
0.023 | 1991719 | 1 |
0.024 | 234999 | 2 |
0.025 | 150000 | 1 |
0.026 | 53847 | 1 |
0.027 | 162000 | 2 |
Last trade - 14.47pm 18/10/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |